Washington D.c., DC10 Active Studies

Multiple Myeloma Clinical Trials in Washington D.c., DC

Find 10 actively recruiting multiple myeloma clinical trials in Washington D.c., DC. Connect with local research sites and explore new treatment options.

10
Active Trials
10
Sponsors
2,827
Enrolling

Recruiting Multiple Myeloma Studies in Washington D.c.

RecruitingWashington D.c., DCNCT05317416

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myelo...

760 participants
Pfizer
View Study Details
RecruitingWashington D.c., DCNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingWashington D.c., DCNCT06858579

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....

480 participants
Dianthus Therapeutics
View Study Details
RecruitingWashington D.c., DCNCT06455449

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease a...

240 participants
AstraZeneca
View Study Details
RecruitingWashington D.c., DCNCT06722235

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it ...

171 participants
Takeda
View Study Details
RecruitingWashington D.c., DCNCT07032662

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP....

162 participants
Immunovant Sciences GmbH
View Study Details
RecruitingWashington D.c., DCNCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingWashington D.c., DCNCT05199311

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM....

66 participants
Hackensack Meridian Health
View Study Details
RecruitingWashington D.c., DCNCT06544499

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, el...

63 participants
argenx
View Study Details
RecruitingWashington D.c., DCNCT06721013

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...

58 participants
Eli Lilly and Company
View Study Details

About Multiple Myeloma Clinical Trials in Washington D.c.

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 10 multiple myeloma clinical trials recruiting participants in Washington D.c., DC. These studies are seeking a combined 2,827 participants. Research is being sponsored by Pfizer, Immunocore Ltd, Dianthus Therapeutics and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Washington D.c. — FAQ

Are there multiple myeloma clinical trials in Washington D.c.?

Yes, there are 10 multiple myeloma clinical trials currently recruiting in Washington D.c., DC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Washington D.c.?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Washington D.c. research site will contact you about next steps.

Are clinical trials in Washington D.c. free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Washington D.c. studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 10 active trials in Washington D.c. are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated March 2, 2026 from ClinicalTrials.gov